<DOC>
	<DOCNO>NCT01105481</DOCNO>
	<brief_summary>This study include two main component : first screen phase second clinical intervention phase . During screen phase , subject poor response clozapine carefully evaluate chart-review clinical assessment . Via chart-review , clinical data diagnosis , disease course previous treatment outcome , concomitant psychotropic agent obtain . Clinical phenomenology , include psychopathology , psychotic mood symptom severity side effect psychotropic medication assess clinical interview observation , conduct experienced clinician . Blood sample also obtain subject measure baseline clozapine drug level extract DNA analysis . Subjects fulfil criterion treatment-resistant schizophrenia poor response adequate dose duration clozapine treatment eligible clinical trial phase 14-week randomize , placebo-controlled amisulpride add-on study . In phase , subject randomly allocate amisulpride augmentation treatment group placebo treatment group . Subjects former group receive clozapine amisulpride combination treatment , latter group receive clozapine placebo . Outcomes clinical efficacy safety carefully evaluate experienced well-trained research stuff 14 week clinical study period . All study conduct four hospital , include DOH Bali Psychiatric Hospital , DOH Tao-yan Psychiatric hospital , Ju-Shang Psychiatric Hospital . Subjects recruit chronic in-patient setting three hospital .</brief_summary>
	<brief_title>Amisulpride Augmentation Therapy Clozapine-resistant Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>DSMIV diagnose schizophrenic patient ; Age 18 60 ; Before treatment clozapine , document treatment failure two antipsychotic adequate duration 6 week sufficient dose 600 mg/day chlorpromazine equivalent ; Documented failure show satisfactory clinical response adequate clozapine treatment , define least clozapine 300 mg/day 3 month plasma drug level 350ng/ml ; At least moderately ill , defined Clinical Global Impression ( CGI ) great 4 PANSS total score great 75 ; Persistent positive psychotic symptom , rating score moderate bad least two four positive symptom item ( delusion , conceptual disorganization , hallucinatory behavior , suspiciousness/persecution ) Positive Negative Syndrome Scale ( PANSS ) ; Patients concomitant treatment lithium , anticonvulsant , antidepressant antipsychotic medication ; Patients underlie severe medical illness , cardiovascular disease , cerebrovascular disease , bone marrow suppression epilepsy ; Patients comorbid diagnosis substance dependence ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>treatment-resistant schizophrenia</keyword>
	<keyword>clozapine</keyword>
	<keyword>amisulpride</keyword>
</DOC>